CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

BioSpace
Original article

Kolon TissueGene cuts 37 US staffers after Phase 3 fail

Phase 3negativeNegative
AI Analysis

Summary

Kolon TissueGene announced a Phase 3 trial failure and subsequently cut 37 US staff members as part of restructuring initiatives.

Clinical Trial Data

Phase

Phase 3

Primary Endpoint

Not Met

Outcome Details

Phase 3 trial failure

Importance:7/10
Sentiment:
-0.80
Phase 3 failurelayoffsrestructuringjob cuts

Read the original article

Published by BioSpace on August 19, 2026 1:54 PM

Read Original